130 related articles for article (PubMed ID: 17414593)
1. Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression.
McLaughlin T; Hogue SL; Stang PE
Am J Ther; 2007; 14(2):221-5. PubMed ID: 17414593
[TBL] [Abstract][Full Text] [Related]
2. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population.
Stang P; Suppapanaya N; Hogue SL; Park D; Rigney U
Am J Ther; 2007; 14(3):241-6. PubMed ID: 17515697
[TBL] [Abstract][Full Text] [Related]
3. Better patient persistence with once-daily bupropion compared with twice-daily bupropion.
Stang P; Young S; Hogue S
Am J Ther; 2007; 14(1):20-4. PubMed ID: 17303971
[TBL] [Abstract][Full Text] [Related]
4. An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey.
Granger AL; Fehnel SE; Hogue SL; Bennett L; Edin HM
J Affect Disord; 2006 Feb; 90(2-3):217-21. PubMed ID: 16360216
[TBL] [Abstract][Full Text] [Related]
5. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients.
Laliberté F; Nelson WW; Lefebvre P; Schein JR; Rondeau-Leclaire J; Duh MS
Adv Ther; 2012 Aug; 29(8):675-90. PubMed ID: 22898791
[TBL] [Abstract][Full Text] [Related]
6. Bupropion extended-release for depressive disorders.
Jefferson JW
Expert Rev Neurother; 2008 May; 8(5):715-22. PubMed ID: 18457528
[TBL] [Abstract][Full Text] [Related]
7. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin.
LaFleur J; Thompson CJ; Joish VN; Charland SL; Oderda GM; Brixner DI
Ann Pharmacother; 2006; 40(7-8):1274-9. PubMed ID: 16849622
[TBL] [Abstract][Full Text] [Related]
8. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
9. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
Moss EL; Simpson JS; Pelletier G; Forsyth P
Psychooncology; 2006 Mar; 15(3):259-67. PubMed ID: 16041840
[TBL] [Abstract][Full Text] [Related]
10. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study.
Ye X; Gross CR; Schommer J; Cline R; St Peter WL
Clin Ther; 2007 Dec; 29(12):2748-57. PubMed ID: 18201593
[TBL] [Abstract][Full Text] [Related]
11. Effect of medication burden on persistent use of lipid-lowering drugs among patients with hypertension.
Robertson TA; Cooke CE; Wang J; Shaya FT; Lee HY
Am J Manag Care; 2008 Nov; 14(11):710-6. PubMed ID: 18999905
[TBL] [Abstract][Full Text] [Related]
12. Factors related to antipsychotic oversupply among Central Texas Veterans.
Yang M; Barner JC; Worchel J
Clin Ther; 2007 Jun; 29(6):1214-25. PubMed ID: 17692735
[TBL] [Abstract][Full Text] [Related]
13. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
14. Depression in patients with type 2 diabetes: impact on adherence to oral hypoglycemic agents.
Kalsekar ID; Madhavan SS; Amonkar MM; Makela EH; Scott VG; Douglas SM; Elswick BL
Ann Pharmacother; 2006 Apr; 40(4):605-11. PubMed ID: 16551768
[TBL] [Abstract][Full Text] [Related]
15. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada.
Hanley DA; Zhang Q; Meilleur MC; Mavros P; Sen SS
Curr Med Res Opin; 2007 Jun; 23(6):1473-80. PubMed ID: 17559742
[TBL] [Abstract][Full Text] [Related]
16. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database.
Jackson KC; Sheng X; Nelson RE; Keskinaslan A; Brixner DI
Clin Ther; 2008 Aug; 30(8):1558-63. PubMed ID: 18803997
[TBL] [Abstract][Full Text] [Related]
17. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients.
Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
Med Care; 2008 Nov; 46(11):1125-33. PubMed ID: 18953222
[TBL] [Abstract][Full Text] [Related]
18. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
Evins AE; Cather C; Culhane MA; Birnbaum A; Horowitz J; Hsieh E; Freudenreich O; Henderson DC; Schoenfeld DA; Rigotti NA; Goff DC
J Clin Psychopharmacol; 2007 Aug; 27(4):380-6. PubMed ID: 17632223
[TBL] [Abstract][Full Text] [Related]
19. Patient adherence to prescribed potassium supplement therapy.
Halpern MT; Irwin DE; Brown RE; Clouse J; Hatziandreu EJ
Clin Ther; 1993; 15(6):1133-45; discussion 1120. PubMed ID: 8111810
[TBL] [Abstract][Full Text] [Related]
20. Delirium associated with concomitant use of low-dose bupropion sustained release and fluoxetine.
Chan CH; Liu HC; Huang MC
J Clin Psychopharmacol; 2006 Dec; 26(6):677-9. PubMed ID: 17110836
[No Abstract] [Full Text] [Related]
[Next] [New Search]
